Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | MGLL | Q99685 | 5/20 | 0.89 |
| ▸ | FAAH | O00519 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.60 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380287 | 0.92 | GSK3A (1.00) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL9816491 | 0.92 | GSK3A (1.00) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL211905 | 0.88 | GSK3A (1.00) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL10717597 | 0.86 | GSK3A (0.87) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL18353726 | 0.81 | GSK3A (0.68) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL10974744 | 0.80 | GSK3A (0.67) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL10973728 | 0.80 | GSK3A (0.67) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL40501 | 0.78 | GSK3A (0.65) | GSK3AGSK3BMGLLFAAHALDH1A1 | |
| SCHEMBL45050 | 0.78 | TDP1 (0.86) | GSK3AGSK3BALDH1A1PKMALDH2 | |
| SCHEMBL30371663 | 0.78 | TDP1 (0.86) | GSK3AGSK3BALDH1A1PKMALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109627360-B | Agglomerated propylene containing thermally reversible crosslinking group and preparation method thereof | 江苏中煦聚烯烃研究院有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-110527019-B | Bismaleimide resin microsphere and preparation method thereof | 北京化工大学 | 2021-04-02 | — | — | CN | claimed |
| CN-109627360-A | One kind containing thermal reversion crosslinked group polypropylene and preparation method thereof | 江苏中煦聚烯烃研究院有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-114853642-A | Synthesis method for directly alkylating benzyl position of aromatic compound | 西湖大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-113880986-A | High-temperature high-pressure hydrolysis-resistant bismaleimide resin composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-111316986-B | Application of maleimide compound as chitin synthetase inhibitor | 浙江工业大学 | 2021-10-15 | — | — | CN | disclosed |
| CN-109627360-B | Agglomerated propylene containing thermally reversible crosslinking group and preparation method thereof | 江苏中煦聚烯烃研究院有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-110527019-B | Bismaleimide resin microsphere and preparation method thereof | 北京化工大学 | 2021-04-02 | — | — | CN | disclosed |
| CN-111316986-A | Application of maleimide compound as chitin synthetase inhibitor | 浙江工业大学 | 2020-06-23 | — | — | CN | disclosed |
| CN-109627360-A | One kind containing thermal reversion crosslinked group polypropylene and preparation method thereof | 江苏中煦聚烯烃研究院有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109453167-A | Maleimide class compound is preparing the application in Li Shiman protozoon insecticide | 浙江工业大学 | 2019-03-12 | — | — | CN | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | GSK3A 3405/4885GSK3B 2941/4885MGLL 2627/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885MGLL 3880/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885MGLL 1555/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | GSK3A 2120/4885GSK3B 2300/4885MGLL 4580/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | GSK3A 3405/4885GSK3B 2941/4885MGLL 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.